These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35388635)

  • 21. Immuno-PET imaging of
    Liu Q; Jiang L; Li K; Li H; Lv G; Lin J; Qiu L
    Cancer Immunol Immunother; 2021 Jun; 70(6):1721-1733. PubMed ID: 33386467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
    Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
    Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and Bioevaluation of
    Hu X; Lv G; Hua D; Zhang N; Liu Q; Qin S; Zhang L; Xi H; Qiu L; Lin J
    Mol Pharm; 2023 Aug; 20(8):4228-4235. PubMed ID: 37409670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression.
    Zhang L; Zhang S; Wu W; Wang X; Shen J; Wang D; Hu K; Zhang MR; Wang F; Wang R
    J Vis Exp; 2023 Feb; (192):. PubMed ID: 36806629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis.
    Zyla E; Musielak B; Holak TA; Dubin G
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promising potential of a
    Lv G; Miao Y; Chen Y; Lu C; Wang X; Xie M; Qiu L; Lin J
    Bioorg Chem; 2021 Oct; 115():105294. PubMed ID: 34426150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
    Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
    Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
    Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues.
    Natarajan A; Patel CB; Ramakrishnan S; Panesar PS; Long SR; Gambhir SS
    Clin Cancer Res; 2019 Mar; 25(6):1774-1785. PubMed ID: 30373750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and Preliminary Evaluations of [
    Maier P; Riehl G; Israel I; Samnick S
    Curr Cancer Drug Targets; 2023; 23(5):412-424. PubMed ID: 36281866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Site-Specific Immuno-PET Tracer to Image PD-L1.
    Wissler HL; Ehlerding EB; Lyu Z; Zhao Y; Zhang S; Eshraghi A; Buuh ZY; McGuth JC; Guan Y; Engle JW; Bartlett SJ; Voelz VA; Cai W; Wang RE
    Mol Pharm; 2019 May; 16(5):2028-2036. PubMed ID: 30875232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and Biologic Evaluation of a Novel
    Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
    J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging.
    Miao Y; Lv G; Chen Y; Qiu L; Xie M; Lin J
    Bioorg Med Chem Lett; 2020 Dec; 30(24):127572. PubMed ID: 32979488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis, and Biological Evaluation of
    Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
    Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 ImmunoPET on the basis of Avidin/Biotin pre-targeted cancer imaging.
    Guo Z; Zhu L; Xu W; Luo X; Chen H; Li X; Zuo C
    Biochem Biophys Res Commun; 2023 Sep; 673():23-28. PubMed ID: 37354656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
    Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immuno-PET Imaging of
    Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
    Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.